Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Wilken, Reason ^a   Veena, Mysore S ^a,b   Wang, Marilene B ^a,b   Srivatsan, Eri S ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; CYTOKINE; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MYC PROTEIN; NITRIC OXIDE SYNTHASE; PACLITAXEL; PEMETREXED; PROTEIN BCL 2; RIDAFOROLIMUS; SORAFENIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL DEATH; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; METASTASIS; NONHUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; ANIMAL; CHEMISTRY; DRUG EFFECT; HEAD AND NECK TUMOR; PATHOLOGY;

CURCUMA LONGA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CURCUMIN; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 79551639050     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-12     Document Type: Review

References (219)

1. Stell PM. Survival time in end-stage head and neck cancer. Eur J Surgical Oncol 1989, 15:407-410.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993, 328:184-194. 10.1056/NEJM199301213280306, 8417385.
3. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK. SEER Cancer Statistics Review 1975-2007. National Cancer Institute. Bethesda, MD
4. Syrjänen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010, Suppl 7:vii243-vii245.
5. Posner MR. Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. Ann Oncol 2010, Suppl 7:vii246-vii251.
6. Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK. Longitudinal oncology registry of head and neck carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 2010,
7. Yip H, Chopra R, Chakrabarti R, Veena MS, Ramamurthy B, Srivatsan ES, Wang MB. Cisplatin-induced growth arrest of head and neck cancer correlates with increased expression of p16 and p53. Arch Otolaryngology Head and Neck Surgery 2006, 132:317-326.
8. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004, 22:1743-1752. 10.1200/JCO.2004.06.147, 15117998.
9. Chandana SR, Conley BA. Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects. Curr Opin Oncol 2009, 21:218-223. 10.1097/CCO.0b013e328329abe5, 19370805.
10. Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck 2010, 32:221-228. 2967367, 19557750.
11. Vissink A, Jansma J, Spigkervet FKL, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003, 14:199-212. 10.1177/154411130301400305, 12799323.
12. Thorn JJ, Hansen HS, Spetch L, Bastholt L. Osteoradionecrosis of the jaws: clinical characteristics and relation to field of irradiation. J Oral Maxillofac Surg 2000, 58:1088-1093. 10.1053/joms.2000.9562, 11021701.
13. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004, 10:1956-1962. 10.1158/1078-0432.CCR-03-1077, 15041712.
14. Bonner JA, Harai PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Eng J Med 2006, 354:567-578.
15. Bonner JA, Harai PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomised trial and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-8. 10.1016/S1470-2045(09)70311-0, 19897418.
16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127. 10.1056/NEJMoa0802656, 18784101.
17. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112:2710-2719. 10.1002/cncr.23442, 18481809.
18. Chattopadhyay I, Biswas K, Bandyopadhyay U, Banerjee RK. Turmeric and curcuminBiological actions and medicinal applications. Curr Sci 2004, 87:44-50.
19. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcima longa: A review of preclinical and clinical research. Altern Med Rev 2009, 14:141-153.
20. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007, 595:1-75. full_text, 17569205.
21. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991, 57:1-7. 10.1055/s-2006-960004, 2062949.
22. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23:363-398.
23. Sreejayan Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994, 46:1013-1016.
24. Masuda T, Maekawa T, Hidaka K, Bando H, Takeda Y, Yamaguchi H. Chemical studies on antioxidant mechanisms of curcumin: analysis of oxidative coupling products from curcumin and linoleate. J Agric Food Chem 2001, 49:2539-2547. 10.1021/jf001442x, 11368633.
25. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin--cellular and molecular mechanisms of action. Crit Rev Food Sci Nut 2004, 44:97-111.
26. Joe B, Lokesh BR. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochem Biophys Acta 1994, 1224:255-263. 10.1016/0167-4889(94)90198-8, 7981240.
27. Brouet I, Ohshima H. Curcumin, an anti-tumour and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995, 206:533-540. 10.1006/bbrc.1995.1076, 7530002.
28. Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998, 55:1955-1962. 10.1016/S0006-2952(98)00114-2, 9714315.
29. Jung KK, Lee HS, Cho JY, Shin WC, Rhee MH, Kim TG, Kang JH, Kim SH, Hong S, Kang SY. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci 2006, 79:2022-2031. 10.1016/j.lfs.2006.06.048, 16934299.
30. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's Disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009, 4:434-444.
31. He LF, Chen HJ, Qian LH. Curcumin protects pre-oligodendrocytes from activated microglia in vitro and in vivo. Brain Res 2010, 1339:60-69. 10.1016/j.brainres.2010.04.014, 20403340.
32. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995, 49:1551-1556. 10.1016/0006-2952(95)00171-U, 7786295.
33. Singh S, Aggarwal BB. Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995, 270:24995-25000. 10.1074/jbc.270.25.14867, 7559628.
34. Brennan P, O'Neill LA. Inhibition of nuclear factor kappaB by direct modification in whole cells: Mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998, 55:965-973. 10.1016/S0006-2952(97)00535-2, 9605420.
35. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999, 163:3474-3483.
36. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-6020. 10.1038/sj.onc.1202980, 10557090.
37. Chuang SE, Cheng AL, Lin JK, Kuo ML. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 2000, 38:991-995. 10.1016/S0278-6915(00)00101-0, 11038236.
38. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemoprotective activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutation Res 2001, 480-481:243-268.
39. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. Basal levels and patterns of anticancer drug-induced activation of nuclear factor kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002, 63:1709-1716. 10.1016/S0006-2952(02)00931-0, 12007574.
40. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS. Curcumin downregulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002, 21:825-30.
41. Han SS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 2002, 35:337-342.
42. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101:1053-1062. 10.1182/blood-2002-05-1320, 12393461.
43. Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 2003, 24:1515-1524. 10.1093/carcin/bgg107, 12844482.
44. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003, 24:1269-1279. 10.1093/carcin/bgg078, 12807725.
45. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling. Int J Cancer 2004, 111:679-692. 10.1002/ijc.20333, 15252836.
46. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005, 11:7490-7498. 10.1158/1078-0432.CCR-05-1192, 16243823.
47. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappa B signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 2004, 1030:578-586. 10.1196/annals.1329.067, 15659840.
48. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES, Wang MB. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 2005, 11:6994-7002. 10.1158/1078-0432.CCR-05-0301, 16203793.
49. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 2006, 118:765-772. 10.1002/ijc.21389, 16106398.
50. Marin YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007, 17:274-283. 10.1097/CMR.0b013e3282ed3d0e, 17885582.
51. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C, Jochum M, Nerlich AG, Pfeffer U. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NF-kappaB. Carcinogenesis 2008, 29:779-789. 10.1093/carcin/bgm248, 17999991.
52. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS. Curcumin inhibits NF-kappa B mediated radioprotection and modulates apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 2008, 7:569-576.
53. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008, 14:6228-6236. 10.1158/1078-0432.CCR-07-5177, 18829502.
54. Fiorillo C, Becatti M, Pensalfini A, Cecchi C, Lanzilao L, Donzelli G, Nassi N, Giannini L, Borchi E, Nassi P. Curcumin protects cardiac cells against ischemia reperfusion injury: effects on oxidative stress, NF-kappaB and JNK pathways. Free Radic Biol Med 2008, 45:839-846. 10.1016/j.freeradbiomed.2008.06.013, 18638545.
55. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S. Curcumin suppresses constitutive activation of nuclear-factor kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008, 7:3318-3329. 10.1158/1535-7163.MCT-08-0541, 18852135.
56. Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor kappa B in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in breast cancer nude mice model. Breast J 2009, 15:223-9. 10.1111/j.1524-4741.2009.00709.x, 19645775.
57. Panicker SR, Kartha CC. Curcumin attenuates glucose-induced monocyte chemoattractant protein-1 synthesis in aortic endothelial cells by modulating the nuclear-factor kappaB pathway. Pharmacology 2010, 85:18-26. 10.1159/000262325, 19955845.
58. Barnes PJ, Karin M. Nuclear factor-κB, a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071. 10.1056/NEJM199704103361506, 9091804.
59. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699. 10.1038/nature02794, 15258597.
60. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684. 10.1038/sj.onc.1209954, 17072321.
61. Brasier AR. The NF-κB regulatory network. Cardiovasc Toxicol 2006, 6:111-130. 10.1385/CT:6:2:111, 17303919.
62. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
63. Gilmore TD. The Rel/NF-κB signal transduction pathway: introduction. Oncogene 1999, 18:6842-6844. 10.1038/sj.onc.1203237, 10602459.
64. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degredation of IκB(α): correlation with induction of cyclooxygenase-2. Carcinogenesis 2002, 23:1511-1518. 10.1093/carcin/23.9.1511, 12189195.
65. Garg A, Aggarwal BB. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 2002, 16:1053-1068. 10.1038/sj.leu.2402482, 12040437.
66. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C. Constitutive activation of transcription factors NF-(κ)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999, 26:119-129. 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N, 10506755.
67. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C. Nuclear NFkappa-B p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 2009, 15:5974-5984. 10.1158/1078-0432.CCR-09-1352, 2760015, 19789307.
68. Ghosh S, Karin M. Missing pieces of the NF-κB puzzle. Cell 2002, 109((Suppl)):S81-96. 10.1016/S0092-8674(02)00703-1, 11983155.
69. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999, 39:41-47. 10.1006/phrs.1998.0404, 10051376.
70. Rao CV. Regulation of COX and LOX by curcumin. Adv Exp Med Biol 2007, 595:213-26. full_text, 17569213.
71. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991, 51:813-819.
72. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999, 20:445-451. 10.1093/carcin/20.3.445, 10190560.
73. Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 2009, 8:2348-2355. 10.1158/1535-7163.MCT-09-0290, 19671757.
74. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21(21):8370-8377.
75. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901. 10.1074/jbc.M404751200, 15590663.
76. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin as maintainance therapy for ulcerative colitis: randomized, multi-center, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506. 10.1016/j.cgh.2006.08.008, 17101300.
77. Yadav VR, Suresh S, Devi K, Yadav S. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 2009, 3:311-321.
78. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 2005, 125:109-116. 10.1016/j.jss.2004.11.009, 15836859.
79. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006, 26:85-90. 10.1161/01.ATV.0000191635.00744.b6, 16239599.
80. Babu PS, Srinivasan K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in an albino rat. Mol Cell Biochem 1995, 152:13-21.
81. Meghana K, Sanjeev G, Ramesh B. Curcumin prevents streptozoin-induced islet damage by scavenging free radicals: a prophylactic and protective role. Eur J Pharmacol 2007, 577:183-191. 10.1016/j.ejphar.2007.09.002, 17900558.
82. Ram A, Das M, Ghosh B. Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs. Biol Pharm Bull 2003, 26:1021-1024. 10.1248/bpb.26.1021, 12843631.
83. Moon DO, Kim MO, Lee HJ. Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide. Biochem Biophys Res Commun 2008, 375:275-279. 10.1016/j.bbrc.2008.08.025, 18706396.
84. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000, 275:444-450. 10.1074/jbc.275.1.444, 10617637.
85. Mun SH, Kim HS, Kim JW, Ko NY. Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCdelta/JNK/C-Jun pathway. J Pharmacol Sci 2009, 111:13-21. 10.1254/jphs.09134FP, 19763044.
86. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 2003, 284:G85-95.
87. Durgaprasad S, Pai CG, Vasanthkumar Alvres JF, Namitha S. A pilot study of the antioxidant effects of curcumin in tropical pancreatitis. Indian J Med Res 2005, 122:315-318.
88. Jones EA, Shoskes DA. The effect of mycophenolate mofetil and polyphenolic bioflavinoids on renal ischemia reperfusion injury and repair. J Urol 2000, 163:999-1004. 10.1016/S0022-5347(05)67871-8, 10688038.
89. Chiu J, Khan ZA, Farhangkhoee H. Curcumin prevents diabetes associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 2009, 25:964-972. 10.1016/j.nut.2008.12.007, 19268536.
90. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59. 10.1016/j.biocel.2008.06.010, 2637808, 18662800.
91. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001, 20:7597-7609. 10.1038/sj.onc.1204997, 11753638.
92. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 1997, 8:470-481. 10.1097/00001813-199706000-00010, 9215611.
93. Hanif R, Qiao L, Schiff SJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997, 130:576-584. 10.1016/S0022-2143(97)90107-4, 9422331.
94. Elattar TM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in-vitro. Anticancer Res 2000, 20:1733-1738.
95. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007, 13:3423-3430. 10.1158/1078-0432.CCR-06-3072, 17545551.
96. Siwak DR, Shishodia S, Aggarwal BB, Kuzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005, 104:879-890. 10.1002/cncr.21216, 16007726.
97. Mohandas KM, Desai DC. Epidemiology of digestive tract cancers in India. V. Large and small bowel. Indian J Gastroenterol 1999, 18:118-121.
98. Oda Y. Inhibitory effect of curcumin on SOS functions induced by UV irradiation. Mutat Res 1995, 348:67-73. 10.1016/0165-7992(95)00048-8, 7477054.
99. Thapliyal R, Maru GB. Inhibition of cytochrome p450 isoenzymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001, 39:541-547. 10.1016/S0278-6915(00)00165-4, 11346483.
100. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003, 92:33-38. 10.1034/j.1600-0773.2003.920106.x, 12710595.
101. Krishnaswamy K, Goud VK, Sesikeran B, Mukundan MA, Krishna TP. Retardation of experimental tumorigenesis and reduction in DNA adducts by turmeric and curcumin. Nutr Cancer 1998, 30:163-166. 10.1080/01635589809514657, 9589436.
102. Inano H, Onoda M, Inafuku N, Kubota M, Kamada Y, Osawa T, Kobayashi H, Wakabayashi K. Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. Carcinogenesis 1999, 20:1011-1018. 10.1093/carcin/20.6.1011, 10357781.
103. Collett GP, Robson CN, Mathers JC, Campbell FC. Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 2001, 22:821-825. 10.1093/carcin/22.5.821, 11323404.
104. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973. 10.1242/jcs.01589, 15564374.
105. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB) dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000, 28:1338-1348. 10.1016/S0891-5849(00)00220-3, 10924853.
106. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400. 10.1038/sj.onc.1204383, 11402335.
107. Passegué E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J 2000, 19:2969-2679. 203376, 10856241.
108. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, Aggarwal BB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009, 125:2187-2197. 10.1002/ijc.24593, 19623659.
109. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol 2010, 79:218-228. 10.1016/j.bcp.2009.08.007, 19682434.
110. Park CH, Lee JH, Yang CH. Curcumin derivatives inhibit the formation of Jun-Fos-DNA complex independently of their conserved cysteine residues. J Biochem Mol Biol 2005, 38:474-480.
111. Sa G, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div 2008, 3:14. 10.1186/1747-1028-3-14, 2572158, 18834508.
112. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274:1664-1672. 10.1126/science.274.5293.1664, 8939848.
113. Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med 1998, 4:1103-1106. 10.1038/2594, 9771732.
114. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
115. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007, 59:419-426.
116. Delston RB, Harbour JW. Rb at the interface between cell cycle and apoptotic decisions. Curr Mol Med 2006, 6:713-718.
117. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993, 7:331-342. 10.1101/gad.7.3.331, 8449399.
118. Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, Lee SH, Hong SI. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol 2002, 21:379-383.
119. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Cell Cycle 2007, 6:2953-2961. 10.4161/cc.6.23.4951, 18156803.
120. Senderowicz AM. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003, 52((Suppl 1)):S61-73. 10.1007/s00280-003-0624-x, 12819936.
121. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependant kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996, 68:67-108. full_text, 8712071.
122. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine 2009, 16:916-922. 10.1016/j.phymed.2009.04.008, 19524420.
123. Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009, 325:107-119. 10.1007/s11010-009-0025-5, 19191010.
124. Wang Z, Desmoulin S, Banerjee S, Kong D, Li Y, Deraniyagala RL, Abbruzzese J, Sarkar FH. Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci 2008, 83:293-300. 10.1016/j.lfs.2008.06.017, 2536622, 18640131.
125. Wang Y, Okan I, Szekely L, Klein G, Wiman KG. Bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and Bax. Cell Growth Differ 1995, 6:1071-1075.
126. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 1996, 86:147-157. 10.1016/S0092-8674(00)80085-9, 8689682.
127. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependant manner. J Biol Chem 2005, 280:20059-20068. 10.1074/jbc.M410670200, 15738001.
128. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007, 6:178-184. 10.4161/cbt.6.2.3577, 1852522, 17218783.
129. Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, Zhang X. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 2007, 85:263-270. 10.1007/s11060-007-9421-4, 17594054.
130. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 2005, 280:11641-11647. 10.1074/jbc.M411781200, 15659383.
131. Lu HF, Lai KC, Hsu SC, Lin HJ, Yang MD, Chen YL, Fan MJ, Yang JS, Cheng PY, Kuo CL, Chung JG. Curcumin induces apoptosis through FAS and FADD, in caspase-3-dependent and -independent pathways in the N18 mouse-rat hybrid retina ganglion cells. Oncol Rep 2009, 22:97-104.
132. Bush JA, Cheung KJ, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001, 271:305-314. 10.1006/excr.2001.5381, 11716543.
133. Freudlsperger C, Greten J, Schumacher U. Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. Anticancer Res 2008, 28:209-214.
134. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008, 7:16. 10.1186/1476-4598-7-16, 2249593, 18226269.
135. Singletary K, Milner J. Diet, autophagy and cancer: a review. Cancer Epidemiol Biomarkers Prev 2008, 17:1596-1610. 10.1158/1055-9965.EPI-07-2917, 18628411.
136. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004, 16:663-669. 10.1016/j.ceb.2004.09.011, 15530778.
137. Indelicato M, Pucci B, Schito L, Reali V, Aventaggiato M, Mazzarino MC, Stivala F, Fini M, Russo MA, Tafani M. Role of hypoxia and autophagy in MDA-MB-231 invasiveness. J Cell Physiol 2010, 223:359-368.
138. Kang C, Avery L. To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation. Autophagy 2008, 4:82-84.
139. Alva AS, Gultekin SH, Baehrecke EH. Autophagy in human tumors: cell survival or death?. Cell Death Differ 2004, 11:1046-1048. 10.1038/sj.cdd.4401445, 15143348.
140. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumor cells. J Cell Mol Med 2009, 13:3644-3654. 10.1111/j.1582-4934.2009.00663.x, 20196784.
141. Li J, Qin Z, Liang Z. The prosurvival role of autophagy in resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer 2009, 9:215. 10.1186/1471-2407-9-215, 2717978, 19566920.
142. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009, 119:1109-1123. 10.1172/JCI35660, 2673867, 19363292.
143. Namgoong GM, Khanal P, Cho HG, Lim SC, Oh YK, Kang BS, Shim JH, Yoo JC, Choi HS. The prolyl-isomerase pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J Biol Chem 2010, 285:23829-23841. 10.1074/jbc.M109.092874, 20479004.
144. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008, 7:2977-2987. 10.1158/1535-7163.MCT-08-0447, 18790778.
145. Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, Huang LL, Zhu F, Wu G. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010, 25:75-80. 10.1089/cbr.2009.0701, 20187799.
146. Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M, Wei L. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 2009, 5:1131-1144. 10.4161/auto.5.8.9996, 19786832.
147. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676. 10.1038/45257, 10604474.
148. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003, 100:15077-15082. 10.1073/pnas.2436255100, 299911, 14657337.
149. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112:1809-1820. 297002, 14638851.
150. Bursch W, Ellinger A, Kienzl H, Török L, Pandey S, Sikorska M, Walker R, Hermann RS. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996, 17:1595-1607. 10.1093/carcin/17.8.1595, 8761415.
151. Górka M, Daniewski WM, Gajkowska B, Lusakowska E, Godlewski MM, Motyl T. Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel. Anticancer Drugs 2005, 16:777-788.
152. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003, 63:2103-2108.
153. Qian W, Liu J, Jin J, Ni W, Xu W. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 2007, 31:329-339. 10.1016/j.leukres.2006.06.021, 16882451.
154. Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy 2010, 6:353-365. 10.4161/auto.6.3.11229, 20200477.
155. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, Schätzl HM. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007, 21:936-942.
156. Basciani S, Vona R, Matarrese P, Ascione B, Mariani S, Cauda R, Gnessi L, Malorni W, Straface E, Lucia MB. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. FEBS Lett 2007, 581:5897-5903. 10.1016/j.febslet.2007.11.069, 18061581.
157. Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007, 14:548-558. 10.1038/sj.cdd.4402030, 16946731.
158. Gewirtz DA, Hilliker ML, Wilson EN. Promotion of autophagy as a mechanism for radiation sensitization of breast cancer cells. Radiother Oncol 2009, 92:323-328. 10.1016/j.radonc.2009.05.022, 19541381.
159. Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 2009, 41:341-351. 10.1093/abbs/gmp028, 19430698.
160. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, Kalkanis SN, Mikkelsen T, Brodie C. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125:717-722. 10.1002/ijc.24402, 19431142.
161. Jia YL, Li J, Qin ZH, Liang ZQ. Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. J Asian Nat Prod Res 2009, 11:918-928. 10.1080/10286020903264077, 20183254.
162. O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR. Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer 2009, 101:1585-1595. 2778521, 19809435.
163. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007, 72:29-39. 10.1124/mol.106.033167, 17395690.
164. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 2007, 3:635-637.
165. Cao Y, Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007, 97:203-224. full_text, 17419947.
166. Barrascout E, Medioni J, Scotte F. Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab. Bull Cancer 2010, 97:29-43.
167. Perry MC, Demeule M, Régina A, Moumdjian R, Béliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 2010,
168. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol 2008, 14:2003-2009. 10.3748/wjg.14.2003, 2701520, 18395899.
169. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007, 13:3423-3430. 10.1158/1078-0432.CCR-06-3072, 17545551.
170. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002, 297:934-942. 10.1016/S0006-291X(02)02306-9, 12359244.
171. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000, 275:10405-10412. 10.1074/jbc.275.14.10405, 10744729.
172. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc 2006, 34:109-115.
173. Ray S, Chattopadhyay N, Mitra A, Siddiqi M, Chatterjee A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol 2003, 22:49-58.
174. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008, 68:3645-3654. 10.1158/0008-5472.CAN-07-2938, 18483246.
175. Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P. Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line. Eur J Pharmacol 2010, 627:8-15. 10.1016/j.ejphar.2009.09.052, 19818349.
176. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005, 11:7490-7498. 10.1158/1078-0432.CCR-05-1192, 16243823.
177. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006, 119:1268-1275. 10.1002/ijc.21967, 16642480.
178. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res 2010, 3:331-338.
179. Chang KW, Hung PS, Lin IY, Hou CP, Chen LK, Tsai YM, Lin SC. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. Int J Cancer 2010, 127:9-20. 10.1002/ijc.25383, 20127863.
180. Cohen AN, Veena MS, Srivatsan ES, Wang MB. Supression of Interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 2009, 135:190-197. 10.1001/archotol.135.2.190, 19221248.
181. Lin L, Hutzen B, Ball S, Foust E, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li C, Li PK, Fuchs J, Lin J. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci 2009, 100:1719-1727. 10.1111/j.1349-7006.2009.01220.x, 19558577.
182. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007, 6:2139-2148. 10.1158/1535-7163.MCT-07-0120, 17699713.
183. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 2009, 6:192-199. 10.2174/157016309789054933, 19496751.
184. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005, 104:1322-1331. 10.1002/cncr.21300, 16092118.
185. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007, 6:1276-1282. 10.1158/1535-7163.MCT-06-0556, 17431105.
186. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res 2009, 29:1895-1899.
187. Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smelley CL, Caldito G, Abreo F, Nathan CA. Curcumin Inhibits Carcinogen and Nicotine-induced Mammalian Target of Rapamycin Pathway Activation in Head and Neck Squamous Cell Carcinoma. Cancer Prev Res 2010, 3:1586-1595.
188. Duarte VM, Han EH, Veena MS, Salvado A, Suh JD, Liang L-J, Faull KF, Srivatsan ES, Wang MB. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IkKB protein of the nuclear factor kB. Mol Cancer Ther 2010, 9:2665-2675. 10.1158/1535-7163.MCT-10-0064, 20937593.
189. Khafif A, Lev-Ari S, Vexler A, Barnea I, Starr A, Karaush V, Haif S, Ben-Yosef R. Curcumin: a potential radio-enhancer in head and neck cancer. Laryngoscope 2009, 119:2019-2026. 10.1002/lary.20582, 19655336.
190. Jagetia JC. Radioprotection and radiosensitization by curcumin. Adv Exp Med Biol 2007, 595:301-320. full_text, 17569217.
191. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004, 23:1599-1607. 10.1038/sj.onc.1207284, 14985701.
192. Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB, Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys 2009, 75:534-542. 10.1016/j.ijrobp.2009.06.034, 19735878.
193. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010, 3:11. 10.1186/1757-2215-3-11, 2880315, 20429876.
194. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2006, 100:3983-3988.
195. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukemia after transplanataion into SCID mice. Nature 2004, 17:645-648.
196. Prince ME, Sivanadan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978. 10.1073/pnas.0610117104, 1783424, 17210912.
197. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
198. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-786. 10.1073/pnas.0307618100, 321758, 14711994.
199. O'Brien CA, Pollett A, Gallinger S, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:111-115.
200. Harper L, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head & neck squamous cell carcinoma. J Oral Pathol Med 2007, 36:594-603. 10.1111/j.1600-0714.2007.00617.x, 17944752.
201. Wu A, Veena MS, Basak SA, Wang MB, Srivatsan ES. CD44High head and neck cancer cells demonstrate increased cell growth and chemotherapeutic resistance [Abstract]. Amer Assoc Cancer Res 2010, 51:s3316.
202. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2866-2872. 10.1200/JCO.2005.04.3547, 16717293.
203. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007, 75:788-799. 10.1111/j.1432-0436.2007.00200.x, 17608727.
204. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006, 12:5064-5073. 10.1158/1078-0432.CCR-06-0913, 16951222.
205. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22:77-85. 10.1200/JCO.2004.06.075, 14701768.
206. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1864-1871. 10.1200/JCO.2008.17.0530, 19289630.
207. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010, 28:3336-3343. 10.1200/JCO.2009.27.0397, 20498391.
208. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007, 18:47-51.
209. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10:247-257. 10.1016/S1470-2045(09)70002-6, 2768532, 19201650.
210. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9:288-296. 10.1016/S1470-2045(08)70073-1, 18308254.
211. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007, 67:2160-2168. 10.1158/0008-5472.CAN-06-2449, 17332346.
212. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, Nathan CO. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009, 8:2255-2265. 10.1158/1535-7163.MCT-08-1184, 2758817, 19625495.
213. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858. 10.1158/0008-5472.CAN-06-1377, 17178882.
214. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010, 28:3330-3335. 10.1200/JCO.2009.25.6834, 20498388.
215. Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol 2009, 64:233-241. 10.1007/s00280-008-0853-0, 19011858.
216. Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2010,
217. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 2008, 14:4175-4185. 10.1158/1078-0432.CCR-07-4470, 18593997.
218. Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 2008, 7:1647-1655. 10.1158/1535-7163.MCT-07-2444, 2534142, 18566236.
219. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010, 21:864-870. 10.1093/annonc/mdp390, 19850643.